Number of the records: 1
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or IImyeloid cells surface antigens [II] CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4)
SYS 0148610 LBL 00000naa--2200000-a-4500 005 20250607164755.6 008 180815s2018----xo-----e------------eng-- 040 $a BA006 $b slo 041 0-
$a eng 044 $a xo $c SK 245 10
$a ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or IImyeloid cells surface antigens [II] CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4) / $c Drgoňa L. ... [et al.] 500 $a Clinical microbiology and infections, Jun 24, Suppl.2 (2018), S83-S94 650 12
$7 sllk_us_auth*d009894 $a infekcie oportúnne $x etiológia $x prevencia a kontrola $2 mesh 650 12
$7 sllk_us_auth*d058990 $a terapia molekulárne cielená $x účinky nežiaduce $2 mesh 650 12
$7 sllk_us_auth*d001691 $a terapia biologická $x účinky nežiaduce $2 mesh 650 22
$7 sllk_us_auth*d012449 $a bezpečnosť $2 mesh 650 22
$7 sllk_us_auth*d051918 $a lektín 2 viažuci kyselinu sialovú, podobný imunoglobulínu $x antagonisty a inhibítory $2 mesh 650 22
$7 sllk_us_auth*d017730 $a Ki-1 antigén $x antagonisty a inhibítory $2 mesh 650 22
$7 sllk_us_auth*d051997 $a ADP-ribozyl cykláza 1 $x antagonisty a inhibítory $2 mesh 650 22
$7 sllk_us_auth*d019013 $a antigény CD40 $x antagonisty a inhibítory $2 mesh 650 22
$7 sllk_us_auth*d000071176 $a rodina signálnych molekúl aktivácie lymfocytov $x antagonisty a inhibítory $2 mesh 650 22
$7 sllk_us_auth*d054398 $a receptory CCR4 $x antagonisty a inhibítory $2 mesh 653 2-
$a inotuzumab ozogamicin 653 2-
$a brentuximab vedotín 653 2-
$a daratumumab 653 2-
$a lucatumumab 653 2-
$a anti-SLAMF7/CD319 653 2-
$a elotuzumab 653 2-
$a mogamulizumab 700 1-
$7 sllk_us_auth*p0063373 $a Drgoňa, Ľuboš $u Odd. klinickej hematológie a transfuziológie, Národný onkologický ústav, Katedra klinickej onkológie SZU, Bratislava $4 ant 710 2-
$7 sllk_us_auth*0012742 $a Redakcia Onkológia $4 adp 773 0-
$7 nnas $w sllk_us_cat*0147827 $t Onkológia $x 1336-8176 $d Bratislava : SOLEN, 2018 $g Roč. 13, č. 3 (2018), s. 221
Number of the records: 1